Search Results

ACTICHROME® Heparin (anti-fXa) is a chromogenic assay intended for the quantitative determination of unfractionated and low molecular weight heparins in human plasma. The assay measures the inhibition of factor Xa (fXa) activity by the various heparins. The Electra 900C® was used to determine performance data. This kit is for in vitro diagnostic use.

Device Description

AI/ML Overview

Here's an analysis of the provided text regarding the acceptance criteria and study for the ACTICHROME® Heparin (anti-fXa) device:

1. Table of Acceptance Criteria and Reported Device Performance

The provided text does not explicitly state pre-defined acceptance criteria (e.g., "The device must achieve an R-value of at least X"). Instead, it presents performance data and implies that equivalence to the predicate device is the overarching acceptance criterion. Thus, the "acceptance criteria" are inferred from the demonstrated performance in comparison to the predicate.

Acceptance Criteria (Inferred from Predicate Equivalence)	Reported Device Performance (ACTICHROME Heparin (anti-fXa))
Method Comparison vs. Predicate Device
Positive correlation with predicate device (implied R > 0.8)	Unfractionated Heparin (Lot 007): R = 0.913, Y = 0.843X + 0.003, Sy.x = 0.07
	Unfractionated Heparin (Lot 010): R = 0.859, Y = 0.765X - 0.009, Sy.x = 0.08
	LMW Heparin (Lot 010): R = 0.895, Y = 1.363X - 0.139, Sy.x = 0.14
Precision (Intra-Assay CV%)
Maintain low intra-assay variability (implied < 10%)	Lot 007, Control 6: 3.3%
	Lot 007, Control 3: 5.6%
	Lot 010, 0.5 U/ml UFH: 2.8%
	Lot 010, 0.25 U/ml UFH: 3.6%
	Lot 010, 0.5 U/ml LMWH: 2.9%
	Lot 010, 0.25 U/ml LMWH: 5.1%
Precision (Inter-Assay CV%)
Maintain low inter-assay variability (implied < 15%)	Lot 007, Control 6: 4.1%
	Lot 007, Control 3: 4.8%
	Lot 010, 0.5 U/ml UFH: 4.6%
	Lot 010, 0.25 U/ml UFH: 10.6%
	Lot 010, 0.5 U/ml LMWH: 6.2%
	Lot 010, 0.25 U/ml LMWH: 9.3%
Substantial Equivalence	Declared "substantially equivalent to the commercially available ACTICHROMIS Hopanin (and Tra) in Is ourin (Xa), manufactured by Biopool International, Ventura, CA, in performance and intended use."

2. Sample Sizes Used for the Test Set and Data Provenance

The text describes method comparison studies and precision studies which serve as the test set for device performance.

Method Comparison (Test Set):
- Lot 007 (unfractionated Heparin): N = 92 samples
- Lot 010 (unfractionated Heparin): N = 40 samples
- Lot 010 (LMW Heparin): N = 42 samples
- Data Provenance: Not explicitly stated (e.g., country of origin, retrospective/prospective). It mentions "human plasma" but no further detail.
Precision (Test Set Control Samples):
- Lot 007: 2 control samples run in quadruplicate over 20 runs (N = 80 per control, total 160 measurements).
- Lot 010: 2 control samples run in quadruplicate over 10 runs (N = 40 per control, total 80 measurements).
- Data Provenance: Not explicitly stated. The samples are described as "control samples" and "Control Plasma spiked with..."

3. Number of Experts Used to Establish Ground Truth for the Test Set and Their Qualifications

This device is a chromogenic assay for quantitative determination of heparins. The "ground truth" for such assays is typically established by comparing against a reference method (the predicate device in this case) and assessing analytical performance like precision and accuracy, not by human expert consensus on interpretations. Therefore, the concept of "experts establishing ground truth" as it applies to image analysis or diagnostic interpretation by radiologists, for example, is not relevant here.

4. Adjudication Method for the Test Set

Not applicable. This is a quantitative assay whose performance is assessed against a predicate device and through precision studies, not requiring human adjudication of results in the way a diagnostic interpretation might.

5. Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study

No, an MRMC comparative effectiveness study was not done. This type of study assesses human reader performance, often with and without AI assistance, which is not relevant for a quantitative diagnostic assay like the ACTICHROME® Heparin (anti-fXa) kit.

6. Standalone (Algorithm Only) Performance Study

Yes, the performance data presented (method comparison and precision) represent the standalone performance of the ACTICHROME® Heparin (anti-fXa) assay. It measures the assay's capability to quantify heparin levels. There is no "human-in-the-loop" aspect to its intended use or performance evaluation described.

7. Type of Ground Truth Used

The "ground truth" for this study is essentially the measurement provided by the predicate device for the method comparison, and known concentrations in control samples for the precision studies. It is based on established analytical methods and reference materials, rather than expert consensus, pathology, or outcomes data.

8. Sample Size for the Training Set

The text describes performance studies (method comparison and precision), not a machine learning study with explicit training and test sets in the AI sense. Therefore, there is no specified "training set" for the algorithm itself (as a traditional assay does not have an algorithm that is "trained"). The phrase "training set" typically refers to data used to develop and optimize an AI model. This device is a chromogenic assay kit.

9. How the Ground Truth for the Training Set Was Established

Not applicable as there is no "training set" in the context of an AI algorithm. The device is a chemical assay, and its development would involve standard analytical chemistry and immunoassay development processes to optimize its reagents and protocols.

Ask a Question

Ask a specific question about this device

Page 1 of 1